CalciMedica initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of CalciMedica (CALC) with a Buy rating and $13 price target The company’s lead candidate, Auxora, is a potent and selective intravenous CRAC channel inhibitor in development for multiple acute inflammatory conditions, the analyst tells investors in a research note. The firm says recent results highlight Auxora’s potential in addressing acute inflammatory conditions with large unmet needs and sizable patient populations.